65 results on '"Press, O"'
Search Results
2. Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas
Catalog
Books, media, physical & digital resources
3. Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma
4. A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT
5. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
6. Well-defined single polymer nanoparticles for the antibody-targeted delivery of chemotherapeutic agents
7. Reply to "Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?" Haematologica. 2012;97(11):e45
8. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
9. Gender-related survival differences associated with polymorphic variants of estrogen receptor-β (ERβ) in patients with metastatic colon cancer
10. The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma
11. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms associated with overall survival in women with metastatic colon cancer
12. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation
13. Genomic Polymorphisms of Angiogenesis Pathway Predict Radiosensitivity in Rectal Cancer
14. Molecular determinants of cetuximab efficacy
15. BEAM vs BuMelTT high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell infusion (HSCT) in the treatment of non-Hodgkin’s lymphoma
16. Gene expression profiling associated with risk of recurrence in patients with colorectal cancer
17. Superior outcomes associated with earlier use: Experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin’s lymphoma (NHL)
18. Molecular predictor of irinotecan (CPT-11) efficacy
19. Gender related survival differences associated with polymorphic variants of estrogen receptor beta (ERβ) and epidermal growth fact receptor (EGFR) in patients with metastatic colon cancer
20. Genomic profile associated with clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab
21. Molecular prognostic factors of irinotecan efficacy
22. Association between dinucleotide repeat(CA) polymorphism of nuclear factor kappa-bata(NF-KB) and local recurrence of stage II/III rectal cancer patients treated with chemoradiation
23. Molecular profiling predicts clinical outcome in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin
24. MnSOD and GPx-1 polymorphisms in relation to local recurrence in patients with rectal cancer treated with chemoradiation
25. Genomic profiling as predictor of toxicity in patients with advanced colorectal cancer treated with platinum-based chemotherapy
26. Survival differences related to estrogen receptor beta (ERβ) polymorphism and age in female patients with metastatic colon cancer
27. CD8 immunomagnetic selection and interleukin-15 (IL-15) facilitate the isolation of human CD8+ cytotoxic T-lymphocytes (CTL) genetically engineered to express an anti-CD20 chimeric T-cell receptor (cTCR)
28. Polymorphisms in IL-8 and the GSTP1 are associated with survival of metastatic colorectal cancer patients treated with CPT-11
29. Predictors of vitality (energy/fatigue) in early stage Hodgkin's disease (HD): Results from Southwest Oncology Group (SWOG) Study 9133
30. Genomic profiling as predictor of toxicity in patients with advanced colorectal cancer treated with platinum-based chemotherapy
31. CD8 immunomagnetic selection and interleukin-15 (IL-15) facilitate the isolation of human CD8+ cytotoxic T-lymphocytes (CTL) genetically engineered to express an anti-CD20 chimeric T-cell receptor (cTCR)
32. Association of Cyclin D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225)
33. Molecular profiling predicts clinical outcome in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin
34. Association of Cyclin D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225)
35. Predictors of vitality (energy/fatigue) in early stage Hodgkin's disease (HD): Results from Southwest Oncology Group (SWOG) Study 9133
36. MnSOD and GPx-1 polymorphisms in relation to local recurrence in patients with rectal cancer treated with chemoradiation
37. Polymorphisms in IL-8 and the GSTP1 are associated with survival of metastatic colorectal cancer patients treated with CPT-11
38. Survival differences related to estrogen receptor beta (ERβ) polymorphism and age in female patients with metastatic colon cancer
39. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen
40. Radioimmunotherapy for non-Hodgkin's lymphomas: A historical perspective
41. EVALUATION OF ANTIBODY BIOTINYLATION REAGENTS FOR APPLICATION TO TARGETED RADIOTHERAPY
42. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience
43. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.
44. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
45. Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study
46. Constitutive endocytosis and degradation of CD22 by human B cells.
47. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.
48. PRELIMINARY RESULTS OF A PHASE II TRIAL OF IODINE-131-LABELED ANTI-CD20 (B1) ANTIBODY THERAPY WITH BONE MARROW RESCUE FOR PATIENTS WITH RELAPSED B CELL LYMPHOMAS
49. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.
50. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.